GE Healthcare Life Sciences is now Cytiva
Danaher Corporation acquires GE Healthcare Life Sciences
25 YEARS HVD LIFE SCIENCES
Celebrate with us
More than 25 years in delivering a specialised, streamlined sales process, expert customer support and top quality service! Our core values include continuity and loyalty towards the people we work with: not only customers and suppliers but also to our employees and business partners.
Together we have been Delivering Life Sciences to the World for more than 25 years.
New in our portfolio
Collaboration with CalibreScientific
We are happy to announce our collaboration with Calibre Scientific, a company with headquarters in Los Angeles, California, representing a diverse portfolio of niche life sciences companies in the fields cell & molecular biology, proteomics, applied science & diagnostics.
HVD Vertrieb awarded by Ministry of Health
In September 2018, the United Arab Emirates, Ministry Of Health and Preventive has awarded HVD Vertriebs Ges.m.b.H a dedicated certificate for best services provided to them in 2017.
Product News ViennaLab 2018
ViennaLab releasing the first series of multiplex (mpx) RealFast™ Assays
The ViennaLab multiplex RealFast™ Assays allow to genotype two loci simultaneously and thus save costs and sample material.
Product News Attana 2018
Attana expands collaboration with HVD Life Sciences
Product News Gyros 2018
Gyros Protein Technologies introduces Gyrolab xPand to improve immunoassay workflow, flexibility and speed in biotherapeutic discovery, development and production
Product News Gyros 05/2017
Gyros Protein Technologies introduces next generation Gyrolab Protein A Kit for Biotherapeutics
Kit increases efficiency of residual protein A ligand detection
Uppsala, Sweden, May 10 , 2017: Gyros Protein Technologies AB, a pioneer in automated nanoliter-scale immunoassays and leading provider of peptide synthesizers and reagents, today announced it has launched a new version of its Gyrolab™ Protein A Kit.
Product News Gyros 04/2017
Gyros Protein Technologies introduces a multi-species kit for pharmacokinetic studies
New kit for early-stage biotherapeutic development, optimized for use in Gyrolab™ systems
Uppsala, Sweden, 05 April 2017: Gyros Protein Technologies AB, a pioneer in automated nanoliter-scale immunoassays and leading provider of peptide synthesizers and reagents, announced today it has introduced a new kit for early-stage biotherapeutic pharmacokinetic (PK) studies.
PRODUCT NEWS Gyros 04/2016
Gyros: Finding the best platform for fit-for-purpose ADA assays
Gyrolab system delivers
Determining the immunogenic potential of a therapeutic antibody is a regulatory requirement during clinical development since anti-drug antibodies (ADA) can cause undesirable effects, ranging from loss of drug exposure and efficacy to serious adverse events. Justine Brose and her colleagues at Novimmune SA, Geneva, Switzerland evaluated four platforms to determine which platform and sample pre-treatment procedures could deliver a fit-for-purpose assay for ADA analysis to determine the immunogenicity of the therapeutic antibody Novimab. Of the platforms tested (ELISA and Gyrolab, Meso Scale Discovery, and AlphaLISA platforms) only Gyrolab and MSD platforms met all of their pre-specified assay requirements.
PRODUCT NEWS ViennaLab 05/2015
ViennaLab introduces the RealFast™ Assay!
PRODUCT NEWS Gyros 05/2015
Gyros has developed a sandwich immunoassay kit specific for Chinese Hamster Ovary (CHO) HCP impurities...
PRODUCT NEWS 02/2015
Gyros Launches Nanoliter-scale Immunoassay System Gyrolab xPlore™ at SLAS2015 Conference
PRODUCT NEWS 01/2015
Abacus Diagnostica is first on the market with a CE IVD marked ultra-sensitive POCT GBS!